A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
European Journal of Cancer · 2024
DOI: 10.1016/j.ejca.2024.114008 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Xiaoting Wei und 23 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Melanoma and Sarcoma, Peking University Cancer Hos…. Hauptthemen laut MEDLINE: Melanoma. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Research Institute, Beijing, China.
- Comprehensive Cancer Center (word B7) of Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
- Department of Internal Medicine of Melanoma and Sarcoma, the Third People's Hospital of Zhengzhou, Henan, China.
- Department of Rare Cancer & Head and Neck Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
- State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Zitieren
APA
Wei, X., Zou, Z., Zhang, W., Fang, M., Zhang, X., Luo, Z., Chen, J., Huang, G., Zhang, P., Cheng, Y., Liu, J., Liu, J., Zhang, J., Wu, D., Chen, Y., Ma, X., Pan, H., Jiang, R., Liu, X., …, & Si, L. (2024). A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114008
Vancouver
Wei X, Zou Z, Zhang W, Fang M, Zhang X, Luo Z, et al. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114008
BibTeX
@article{Wei2024,
author = {Wei, Xiaoting and Zou, Zhengyun and Zhang, Weizhen and Fang, Meiyu and Zhang, Xiaoshi and Luo, Zhiguo and Chen, Jing and Huang, Gang and Zhang, Peng and Cheng, Ying and Liu, Jiwei and Liu, Jiyan and Zhang, Junping and Wu, Di and Chen, Yu and Ma, Xiaobiao and Pan, Hongming and Jiang, Renbing and Liu, Xinlan and Ren, Xiubao and Tian, Hongqi and Jia, Zhongwei and Guo, Jun and Si, Lu},
title = {A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma},
journal = {European Journal of Cancer},
year = {2024},
doi = {10.1016/j.ejca.2024.114008}
}
EUVIMED